网站主页 >> CAS数据库列表 >> N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
|
|
|
- CAS号:
- 1831110-54-3
- 英文名:
- MS023
- 英文别名:
- MS023;CS-2284;MS023 (MS-023;Inhibitor,MS 023,MS-023,MS023,inhibit,Histone Methyltransferase;(2-aminoethyl)(methyl)({4-[4-(propan-2-yloxy)phenyl]-1H-pyrrol-3-yl}methyl)amine;N1-Methyl-N1-[[4-[4-(1-methylethoxy)phenyl]-1H-pyrrol-3-yl]methyl]-1,2-ethanediamine;1,2-Ethanediamine, N1-methyl-N1-[[4-[4-(1-methylethoxy)phenyl]-1H-pyrrol-3-yl]methyl]-
- 中文名:
- N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
- 中文别名:
- MS023,细胞活性PRMT抑制剂;人I型PRMTS抑制剂(MS023);N1-((4-(4-异丙氧基苯基)-1H-吡咯-3-基)甲基)-N1-甲基乙烷-1,2-二胺;N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
- CBNumber:
- CB63121120
- 分子式:
- C17H25N3O
- 分子量:
- 287.4
- MOL File:
- 1831110-54-3.mol
|
|
|
N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺化学性质
-
沸点:
-
437.8±45.0 °C(Predicted)
-
|
-
密度:
-
1.075±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
-20°C
-
|
-
溶解度:
-
≥28.7 mg/mL in DMSO; ≥13.7 mg/mL in EtOH; ≥23.3 mg/mL in H2O
-
|
-
形态:
-
powder
-
|
-
酸度系数(pKa):
-
17.44±0.50(Predicted)
-
|
-
颜色:
-
white to light brown
-
|
N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺性质、用途与生产工艺
MS023 是一种有效选择性的，具有细胞活性的人 I 型蛋白精氨酸甲基转移酶 (PRMTs) 抑制剂，对 PRMT1，PRMT3，PRMT4，PRMT6 和 PRMT8 的 IC50 分别为 30，119，83，4 和 5 nM。
IC50: 30 nM (PRMT1), 119 nM (PRMT3), 83 nM (PRMT4), 4 nM (PRMT6), 5 nM (PRMT8)
MS023 (1-1000 nM; 48 hours) inhibits PRMT1 methyltransferase activity in MCF7 cells.
MS023(1-1000 nM; 20 hours) inhibits PRMT6 methyltransferase activity in HEK293 cells.
Western Blot Analysis
|
Cell Line:
|
MCF7 and HEK293 cells
|
|
Concentration:
|
1.4, 4, 12, 37, 111, 333, and 1000 nM
|
|
Incubation Time:
|
48 hours for MCF7 cells; 20 hours for HEK293 cells
|
|
Result:
|
Treatment potently and concentration-dependently reduced cellular levels of H4R3me2a (IC
50
=9±0.2 nM).
Treatment concentration-dependently reduced the H3R2me2a mark (IC
50
=56±7 nM).
|
Administration of MS023 (160 mg/kg, i.p) in combination with PKC412 (100 mg/kg, i.g.) blocks MLL-r acute lymphoblastic leukemia (ALL) propagation by inhibiting maintenance of functional MLL-r ALL-initiating cells.
|
Animal Model:
|
NOD-scid IL2Rgnull (NSG) mice bearing primary MLL-r ALL cells
|
|
Dosage:
|
160 mg/kg
|
|
Administration:
|
Intraperitoneal injection; PKC412 (100 mg/kg, i.g.), MS023 (160 mg/kg, i.p), or a combination for 4 weeks
|
|
Result:
|
Combinatorial treatment extended survival of leukemic mice relative to single treatments.
|
N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/25 | HY-19615 | N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
MS023 | 1831110-54-3 | 2mg | 760元 |
| 2024/01/25 | HY-19615 | N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
MS023 | 1831110-54-3 | 5mg | 1000元 |
N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
生产厂家
1831110-54-3, N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺 相关搜索:
- 合成有机化合物配体
- 细胞生物学试剂
- MS023,细胞活性PRMT抑制剂
- N1-((4-(4-异丙氧基苯基)-1H-吡咯-3-基)甲基)-N1-甲基乙烷-1,2-二胺
- 人I型PRMTS抑制剂(MS023)
- N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
- 1831110-54-3
- Inhibitor,MS 023,MS-023,MS023,inhibit,Histone Methyltransferase
- 1,2-Ethanediamine, N1-methyl-N1-[[4-[4-(1-methylethoxy)phenyl]-1H-pyrrol-3-yl]methyl]-
- MS023 (MS-023
- CS-2284
- (2-aminoethyl)(methyl)({4-[4-(propan-2-yloxy)phenyl]-1H-pyrrol-3-yl}methyl)amine
- N1-Methyl-N1-[[4-[4-(1-methylethoxy)phenyl]-1H-pyrrol-3-yl]methyl]-1,2-ethanediamine
- MS023